Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.34 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CCND3 | P30281 | 1/20 | 0.34 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.32 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.31 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.31 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11839777 | 0.87 | MEN1 (0.37) | MEN1KMT2ARXRA | |
| SCHEMBL5850640 | 0.83 | MEN1 (0.37) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL3910718 | 0.82 | MEN1 (0.42) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL38661507 | 0.82 | MEN1 (0.42) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL5850008 | 0.82 | MEN1 (0.42) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL13223607 | 0.81 | CCNE2 (0.37) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL13223606 | 0.81 | MEN1 (0.35) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL5851896 | 0.79 | CCNE2 (0.38) | CCNE2CDK2CCND3CDK6MEN1 | |
| SCHEMBL5850324 | 0.75 | MEN1 (0.50) | MEN1KMT2A | |
| SCHEMBL5851723 | 0.74 | KCNH2 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056348-B2 | 5-aryl-1,3,3-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibers | WELLA AG (DE) | 2006-06-06 | — | — | US | disclosed |
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | Wella GmbH (DE) | 2003-11-20 | — | — | US | disclosed |
| EP-1280773-A1 | 5-ARYL-1.3.3.-TRIMETHYL-2-METHYLENE-INDOLINE DERIVATIVES AND SALTS THEREOF, METHODS FOR THE PRODUCTION AND USE OF SAID COMPOUNDS FOR THE TEMPORARY COLORATION OF FIBRES | Wella Aktiengesellschaft (DE) | 2003-02-05 | — | — | EP | disclosed |
| WO-2002085854-A1 | 5-ARYL-1.3.3.-TRIMETHYL-2-METHYLENE-INDOLINE DERIVATIVES AND SALTS THEREOF, METHODS FOR THE PRODUCTION AND USE OF SAID COMPOUNDS FOR THE TEMPORARY COLORATION OF FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030213071-A1 | 5-Aryl-1.3.3.-trimethyl-2-methylene-indoline derivatives and salts thereof, methods for the production and use of said compounds for the temporary coloration of fibres | INMT, KRT18, IPO5 | ADORA3 1686/4885CCNE2 1565/4885CDK2 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.